Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 17/20 | 1.00 |
| ▸ | MEN1 | O00255 | 16/20 | 1.00 |
| ▸ | POLB | P06746 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.89 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.77 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.73 |
| ▸ | NPC1 | O15118 | 1/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.73 |
| ▸ | RAB9A | P51151 | 1/20 | 0.73 |
| ▸ | PKM | P14618 | 1/20 | 0.72 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.70 |
| ▸ | KDR | P35968 | 1/20 | 0.69 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.68 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.68 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.68 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.68 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12008882 | 0.94 | KMT2A (1.00) | KMT2AMEN1POLBMAPTALDH1A1 | |
| SCHEMBL12008948 | 0.92 | MEN1 (0.85) | KMT2AMEN1POLBMAPTALDH1A1 | |
| SCHEMBL12008967 | 0.91 | KMT2A (0.84) | KMT2AMEN1POLBMAPTALDH1A1 | |
| SCHEMBL12008987 | 0.90 | MEN1 (1.00) | KMT2AMEN1POLBMAPTALDH1A1 | |
| SCHEMBL4799078 | 0.90 | MEN1 (1.00) | KMT2AMEN1POLBMAPTALDH1A1 | |
| SCHEMBL12008841 | 0.90 | MEN1 (1.00) | KMT2AMEN1POLBMAPTALDH1A1 | |
| SCHEMBL4799090 | 0.90 | MEN1 (1.00) | KMT2AMEN1POLBMAPTALDH1A1 | |
| SCHEMBL12008936 | 0.89 | MEN1 (0.83) | KMT2AMEN1POLBMAPTALDH1A1 | |
| SCHEMBL12008930 | 0.89 | MEN1 (0.83) | KMT2AMEN1POLBMAPTALDH1A1 | |
| SCHEMBL12008953 | 0.89 | MEN1 (0.83) | KMT2AMEN1POLBMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | DASGUPTA RAMANUJ (US) | 2017-02-23 | — | — | US | disclosed |
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | DASGUPTA RAMANUJ (US) | 2017-02-23 | — | — | US | disclosed |
| US-9433611-B2 | Oxazole and thiazole compounds as β-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2016-09-06 | — | — | US | disclosed |
| US-9433611-B2 | Oxazole and thiazole compounds as β-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2016-09-06 | — | — | US | disclosed |
| US-9173871-B2 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2015-11-03 | — | — | US | disclosed |
| US-9173871-B2 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2015-11-03 | — | — | US | disclosed |
| US-20130109675-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | NEW YORK UNIVERSITY | 2013-05-02 | — | — | US | disclosed |
| US-20130109675-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | NEW YORK UNIVERSITY | 2013-05-02 | — | — | US | disclosed |
| US-20120264744-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | UNITED STATES GOVERNMENT | 2012-10-18 | — | — | US | disclosed |
| US-20120264744-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | UNITED STATES GOVERNMENT | 2012-10-18 | — | — | US | disclosed |
| US-8252823-B2 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252823-B2 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2012-08-28 | — | — | US | disclosed |
| US-20090227624-A1 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | US ARMY, SECRETARY OF THE ARMY | 2009-09-10 | — | — | US | disclosed |
| US-20090227624-A1 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | US ARMY, SECRETARY OF THE ARMY | 2009-09-10 | — | — | US | disclosed |
| WO-2009097113-A2 | OXAZOLE AND THIAZOLE COMPOUNDS AS B-CATENIN MODULATORS AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264744-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | CTNNB1, CTNNA1, CTNNBL1 | KMT2A 4503/4885MEN1 3747/4885POLB 2397/4885 |
| US-20090227624-A1 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | CTNNB1, CTNNA1, CTNNBL1 | KMT2A 4591/4885MEN1 4655/4885POLB 2088/4885 |
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | CTNNB1, CTNNA1, CTNNBL1 | KMT2A 4591/4885MEN1 4655/4885POLB 2088/4885 |
| US-20130109675-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | CTNNB1, CTNNA1, CTNNBL1 | KMT2A 4591/4885MEN1 4655/4885POLB 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.